LDL cholesterol reduction
Multiple Italian RCTs demonstrate Bergamonte® (1,000 mg/day) reduces LDL cholesterol by 25–36% — approaching statin-level efficacy for natural supplementation. The brutieridin and melitidin content provides HMG-CoA reductase inhibition directly comparable to statin mechanism, but without the myopathy, liver, and CoQ10 depletion risks associated with pharmaceutical statins.
Triglyceride and VLDL reduction
Bergamonte® consistently reduces triglycerides by 30–40% across clinical trials — one of the most potent natural triglyceride-lowering ingredients available. VLDL cholesterol is also significantly reduced, improving the full atherogenic lipid profile beyond LDL alone.
HDL cholesterol elevation
Unlike most cholesterol-lowering interventions that reduce LDL without raising HDL, Bergamonte® consistently increases HDL cholesterol by 15–40% in clinical trials — a comprehensive lipid panel improvement that reduces overall cardiovascular risk more completely than LDL reduction alone.
Blood glucose and insulin resistance improvement
Bergamonte® significantly reduces fasting blood glucose, postprandial glucose, and insulin resistance in metabolic syndrome patients. AMPK activation improves skeletal muscle glucose uptake and reduces hepatic glucose output — a dual metabolic mechanism explaining why bergamot addresses both lipid and glucose disorders simultaneously.
Statin adjunct and dose reduction support
Clinical trials show Bergamonte® combined with low-dose statins produces greater lipid improvements than either alone, potentially allowing statin dose reduction and reduced side effect risk. This positions Bergamonte® as the premier natural statin-complementary ingredient with direct mechanistic rationale.
HMG-CoA reductase inhibition (statin-like mechanism)
Brutieridin and melitidin — polyphenols unique to Citrus bergamia — contain a hydroxymethylglutaric acid moiety that directly inhibits HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway. This is the identical enzyme inhibited by statin drugs (atorvastatin, rosuvastatin), explaining why bergamot achieves statin-comparable LDL reductions in clinical trials.
AMPK activation and dual metabolic signaling
Bergamot polyphenols activate AMP-activated protein kinase (AMPK) via the LKB1 pathway, stimulating fatty acid oxidation, increasing LDL receptor expression in hepatocytes, improving skeletal muscle glucose uptake, and reducing hepatic glucose production. This AMPK mechanism explains the simultaneous lipid-lowering and glucose-lowering effects.
PCSK9 inhibition and LDL receptor upregulation
Bergamot flavonoids inhibit PCSK9 (proprotein convertase subtilisin/kexin type 9) — the same target as the newest generation of injectable cholesterol-lowering biologics (evolocumab, alirocumab). PCSK9 inhibition prevents LDL receptor degradation, increasing hepatic LDL clearance from the bloodstream.
Randomized, double-blind, placebo-controlled trial of Bergamonte® (500 and 1,000 mg/day) vs. placebo in 237 patients with mixed hyperlipidemia and metabolic syndrome for 30 days.
237 adults with hyperlipidemia and metabolic syndrome. 30-day intervention.
Bergamonte® 1,000 mg/day: LDL reduced 36%, triglycerides reduced 39%, HDL increased 40%, fasting glucose reduced 22%. 500 mg/day: dose-dependent but lesser effects. No serious adverse events. Comparable to low-dose statin efficacy for LDL reduction.
RCT comparing rosuvastatin (10 mg/day) alone vs. rosuvastatin + Bergamonte® (500 mg/day) in 188 statin-intolerant or partially-responding patients for 30 days.
188 patients with statin intolerance or partial response. 30-day intervention.
Bergamot + low-dose statin combination produced significantly greater LDL reductions than statin alone (-45% vs -28%) and greater HDL improvements. Supported statin dose reduction while maintaining efficacy. No increase in adverse effects with combination.
RCT of bergamot polyphenol extract vs. placebo in 107 NAFLD patients for 120 days.
107 NAFLD patients. 120-day intervention.
Bergamot extract significantly reduced liver fat content (ultrasound), liver enzymes (ALT, AST), triglycerides, and fasting glucose. Liver steatosis grade improved. Supports bergamot for liver metabolic health beyond cardiovascular applications.